Revolution Medicines Inc. Common Stock vs Energy Fuels Inc Ordinary Shares (Canada) — how do they compare? Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B), while Energy Fuels Inc Ordinary Shares (Canada) trades at $8.29 (market cap $2.45B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 16.5× Energy Fuels Inc Ordinary Shares (Canada)'s market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, Energy Fuels Inc Ordinary Shares (Canada) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 2 Days and Energy Fuels Inc Ordinary Shares (Canada) for 0 Days on average.
| RVMD | UUUU | |
|---|---|---|
Market Cap | $40.39B | $2.45B |
Volume | 2,941,009 | 7,967,898 |
Sector | Health | Energy |
52-Week High | $221.15 | $27.72 |
52-Week Low | $49.56 | $8.34 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $37.09B | $2.19B |
Signals from Pluang's Aura AI — not financial advice
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →